Depressive Disorder and Anxiety Disorders Clinical Trial
Official title:
A First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK356278 (PDE4 Inhibitor) in Healthy Volunteers
This study will evaluate the safety, tolerability, and pharmacokinetics of GSK356278 in male volunteers
To evaluate the safety, tolerability and pharmacokinetics of single ascending doses of GSK356278 and may assess the effect of food on GSK356278 pharmacokinetics. They study will assess the compound's effect on nausea, emesis and alertness. Close monitoring of cardiovascular parameters will be included. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00536679 -
Relative Bioavailability and Food Effect Study for GSK163090 in Healthy Male and Female Volunteers
|
Phase 1 | |
| Completed |
NCT01424384 -
Emotional Processing in Healthy Volunteers in the Presence of an Investigational Anxiolytic
|
Phase 1 | |
| Completed |
NCT00513565 -
A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00426608 -
To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.
|
Phase 1 | |
| Completed |
NCT00435695 -
Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males
|
Phase 1 | |
| Completed |
NCT00343707 -
PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients
|
Phase 2 | |
| Completed |
NCT01059591 -
First Study in Humans With GSK424887
|
Phase 1 | |
| Completed |
NCT01059578 -
First Study in Humans With GSK206136
|
Phase 1 | |
| Completed |
NCT00703547 -
A First Time in Human Study of GSK586529 in Healthy Volunteers
|
Phase 1 |